若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

EasySep™人ILC2富集试剂盒

对来源于洗涤的白细胞单采术样本的未标记的人 ILC2 细胞进行免疫磁珠负选分离

只有 %1
¥10,414.00

产品号 #(选择产品)

产品号 #17972_C

免疫磁珠负选细胞富集试剂盒

产品优势

  • 快捷、操作简单且无需分离柱
  • 获得无标记的活细胞
  • 便于快速流式分选ILC2

产品组分包括

  • EasySep™人ILC2富集试剂盒(产品号 #17972)
    • EasySep™人ILC2富集抗体混合物,1mL
    • EasySep™ Dextran RapidSpheres™ 50103 磁珠,1mL
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品,请参阅《实验方案与技术文档》

总览

使用 EasySep™ 人 ILC2 富集试剂盒,通过免疫磁珠负选,可轻松高效地从洗涤的白细胞单采样本中分离高纯度的人 2 型固有淋巴样细胞(ILC2)。EasySep™ 技术结合单克隆抗体的特异性与无柱磁系统的简便性,已在发表的研究中广泛应用超过 20 年。

在此 EasySep™ 负选过程中,不需要的细胞通过抗体复合物和磁珠标记。表达以下标记的细胞将被去除:CD2、CD3、CD4、CD14、CD16、CD19、CD24、CD34、CD56、CD61、CD66b、CD123 和 GlyA。使用 EasySep™ 磁极进行无柱分选,磁珠标记的细胞被去除,只需将未标记的目的ILC2 细胞倒入或移取至新的管中即可。完成磁珠分选后,目的 ILC2 细胞可直接用于下游应用,如流式细胞术和细胞分选。

了解更多关于 EasySep™ 免疫磁性技术的工作原理。探索更多优化实验流程的产品,包括培养基、补充物、抗体等。

 

磁极兼容性
• “The Big Easy” EasySep™磁极(产品号 #18001)
• Easy 50 EasySep™磁极(产品号 #18002)
 
分类
细胞分选试剂盒
 
细胞类型
先天性淋巴细胞
 
种属

 
样本来源
白细胞单采术样本
 
分选方法
负选
 
应用
细胞分选
 
品牌
EasySep
 
研究领域
免疫
 

实验数据

Figure 1. Typical EasySep™ Human ILC2 Enrichment Profile

Starting with washed leukapheresis sample, the ILC2 content (Lin-CD45+CD294+CD127+CD161+) of the enriched fraction typically ranges from 13 - 78%. In the above example, the percentages of ILC2s in the start and final enriched fractions are 0.03% and 35.3%, respectively. NOTE: The ILC2 content of the start fraction typically ranges from 0.001 - 0.16%.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
17972
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17972
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17972
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

相关材料与文献

技术资料 (3)

文献 (1)

Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9 Cancer Immunology, Immunotherapy : CII 2025 May

Abstract

ObjectiveThis study investigated the impact of innate lymphoid cell type 2 (ILC2s) on the function of regulatory T cells (Treg) and CD8+ T cells in chronic lymphocytic leukemia (CLL) through IL-9.MethodsPeripheral blood samples were collected from CLL patients (n = 52) and healthy controls (n = 30). ILC2 proportions and IL-9 levels were assessed using flow cytometry and ELISA. Immunofluorescence staining was performed to stain GATA3, CRTH2, and IL-9 in cervical lymph nodes from CLL patients (n = 10) and control subjects with reactive lymphadenitis (n = 10). Correlation analysis between ILC2s and IL-9 was conducted using the Spearman test. ILC2s were sorted and cultured from CLL patients, followed by co-culture experiments with PBMCs of healthy controls and MEC-1 cells, with or without anti-IL-9 antibody intervention. Flow cytometry was used to measure the proportions of ILC2s, Treg cells, PD-1+/TIGIT+/CTLA-4+ Treg subsets, and granzyme B+/perforin+ CD8+ T cells, along with MEC-1 cell apoptosis.ResultsThe proportions of ILC2s and Treg, along with serum IL-9 levels, were significantly elevated in CLL patients (P < 0.05). Peripheral blood ILC2s were positively correlated with IL-9 (r = 0.609, P < 0.001). The average fluorescence intensity of GATA3, CRTH2, and IL-9 in the cervical lymph nodes of CLL patients increased significantly (P < 0.001), and IL-9 showed colocalization with GATA3 and CRTH2. In vitro, IL-9 levels in the supernatant of sorted ILC2s from CLL patients increased. Treatment with anti-IL-9 antibody significantly reduced the PD-1+ Treg and TIGIT+ Treg cells while increasing granzyme B+ CD8+ T cells (P < 0.05). However, there was no significant effect on Treg, CTLA-4+ Treg, and perforin+ CD8+ T cells (P > 0.05). Additionally, anti-IL-9 antibody significantly increased early apoptosis (P < 0.05).ConclusionILC2s affect CD8+ T cells and Treg cells through IL-9, weakening the anti-tumor effects of CD8+ T cells and enhancing the immunosuppressive effects of Treg cells, thereby contributing to CLL pathogenesis.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00262-025-04082-4.

更多信息

更多信息
物种 人类
Magnet Compatibility • “The Big Easy” EasySep™ Magnet (Catalog #18001) • Easy 50 EasySep™ Magnet (Catalog #18002)
样本来源 白细胞单采术样本
Selection Method Negative
标记抗体

质量保证:

本产品仅供科研使用,除非另有说明,不得用于人体或动物的诊断或治疗用途。如需了解 STEMCELL 的质量体系,请访问 www.stemcell.cn/compliance

Copyright © 2025 by STEMCELL Technologies. All rights reserved.

在线联系